[go: up one dir, main page]

MA33194B1 - Anticorps humanisés ayant une activité antitumorale - Google Patents

Anticorps humanisés ayant une activité antitumorale

Info

Publication number
MA33194B1
MA33194B1 MA34251A MA34251A MA33194B1 MA 33194 B1 MA33194 B1 MA 33194B1 MA 34251 A MA34251 A MA 34251A MA 34251 A MA34251 A MA 34251A MA 33194 B1 MA33194 B1 MA 33194B1
Authority
MA
Morocco
Prior art keywords
human antibody
tumor activity
colon cancer
humanized antibodies
human colon
Prior art date
Application number
MA34251A
Other languages
Arabic (ar)
English (en)
Inventor
Norbert Alexander Kienzle
Adam William Clarke
Anthony Gerard Doyle
Philip Anthony Jennings
Matthew Pollard
Original Assignee
Cephalon Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901129A external-priority patent/AU2009901129A0/en
Application filed by Cephalon Australia Pty Ltd filed Critical Cephalon Australia Pty Ltd
Publication of MA33194B1 publication Critical patent/MA33194B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G01N33/5752—
    • G01N33/57525—
    • G01N33/57535—
    • G01N33/57545—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps humanisés et leurs domaines de liaison ayant une activité antitumorale. En particulier, les anticorps humanisés se lient spécifiquement aux cellules tumorales du cancer du colon humain et les tuent directement. Ils présentent également une puissante activité cytotoxique à médiation immunitaire contre les cellules du cancer du colon humain
MA34251A 2009-03-16 2010-03-16 Anticorps humanisés ayant une activité antitumorale MA33194B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16068209P 2009-03-16 2009-03-16
AU2009901129A AU2009901129A0 (en) 2009-03-16 Humanised antibodies with anti-tumour activity
US25851709P 2009-11-05 2009-11-05
PCT/AU2010/000298 WO2010105290A1 (fr) 2009-03-16 2010-03-16 Anticorps humanisés ayant une activité antitumorale

Publications (1)

Publication Number Publication Date
MA33194B1 true MA33194B1 (fr) 2012-04-02

Family

ID=42739039

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34251A MA33194B1 (fr) 2009-03-16 2010-03-16 Anticorps humanisés ayant une activité antitumorale

Country Status (18)

Country Link
US (2) US8470320B2 (fr)
EP (2) EP2408820A4 (fr)
JP (1) JP5746134B2 (fr)
KR (1) KR20110129935A (fr)
CN (1) CN102395604B (fr)
AU (1) AU2010225448B2 (fr)
BR (1) BRPI1009460A2 (fr)
CA (1) CA2769276A1 (fr)
EA (1) EA024695B1 (fr)
IL (1) IL214840A (fr)
MA (1) MA33194B1 (fr)
MX (1) MX2011009704A (fr)
NZ (2) NZ600915A (fr)
SG (1) SG173577A1 (fr)
TN (1) TN2011000417A1 (fr)
UA (1) UA108349C2 (fr)
WO (1) WO2010105290A1 (fr)
ZA (1) ZA201105875B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011054030A1 (fr) 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Traitement d'un cancer caractérisé par la mutation des gènes kras ou braf
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
JP6286532B2 (ja) 2013-04-29 2018-02-28 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3212216A4 (fr) 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Variantes de l'interféron alphaa2b
CN112710843B (zh) * 2020-12-16 2022-11-04 江苏伟禾生物科技有限公司 一种测定群体反应性抗体检测的板式免疫荧光试剂盒及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DE69942636D1 (de) 1998-12-09 2010-09-09 Phyton Holdings Llc Verfahren zur herstellung von glycoprotein mit menschlichem glycosylierungsbild
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US6881557B2 (en) * 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
CN101189265B (zh) * 2005-06-01 2012-07-04 米克罗麦特股份公司 抗il2抗体
EP1878747A1 (fr) 2006-07-11 2008-01-16 greenovation Biotech GmbH Anticorps glyco-modifiés

Also Published As

Publication number Publication date
KR20110129935A (ko) 2011-12-02
WO2010105290A1 (fr) 2010-09-23
IL214840A (en) 2015-11-30
CA2769276A1 (fr) 2010-09-23
IL214840A0 (en) 2011-11-30
JP5746134B2 (ja) 2015-07-08
EA201171133A1 (ru) 2012-03-30
AU2010225448B2 (en) 2013-10-24
UA108349C2 (uk) 2015-04-27
AU2010225448A1 (en) 2011-09-08
EP2433967A3 (fr) 2013-05-01
EA024695B1 (ru) 2016-10-31
US20100297134A1 (en) 2010-11-25
JP2012520329A (ja) 2012-09-06
SG173577A1 (en) 2011-09-29
NZ600915A (en) 2013-09-27
CN102395604A (zh) 2012-03-28
CN102395604B (zh) 2015-11-25
EP2433967A2 (fr) 2012-03-28
TN2011000417A1 (en) 2013-03-27
US8470320B2 (en) 2013-06-25
US8901279B2 (en) 2014-12-02
MX2011009704A (es) 2011-09-28
ZA201105875B (en) 2012-11-28
BRPI1009460A2 (pt) 2016-03-01
EP2408820A1 (fr) 2012-01-25
US20130280246A1 (en) 2013-10-24
NZ594668A (en) 2012-10-26
EP2408820A4 (fr) 2013-01-23

Similar Documents

Publication Publication Date Title
MA33194B1 (fr) Anticorps humanisés ayant une activité antitumorale
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
EP4349868A3 (fr) Anticorps monoclonaux humanisés et chimériques contre cd47
WO2011130434A3 (fr) Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
DE602006012672D1 (de) Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
PE20091342A1 (es) Inmunoglobulinas
WO2010066803A3 (fr) Anticorps humains du facteur tissulaire
WO2008112003A3 (fr) Agents liants cibles diriges contre pdgfr-alpha et utilisations associees
PH12013501177A1 (en) TNF-a BINDING PROTEINS
WO2011110642A3 (fr) Anticorps monoclonaux contre c-met
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2011147982A3 (fr) Anticorps monoclonaux contre l'épitope de her2
NZ591471A (en) Antibodies to ccr2
NO20074063L (no) Monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) som mangler fucosyl residier
EP3520816A3 (fr) Molécules d'anticorps anti-gcc et compositions et procédés associés
MX2012004412A (es) Proteinas de union a il-1.
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
MX2011009312A (es) Formulaciones de anticuerpos humanizados anti-cd19.
EP3539988A3 (fr) Anticorps monoclonaux contre her2
WO2006089133A8 (fr) Anticorps anti-cd19 et leur utilisation en oncologie
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
WO2010100056A3 (fr) Anticorps contre le ligand a induisant la prolifération (april)
EA020130B9 (ru) Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата